While targeting oncogenic drivers such as Cyclin D1 and Ano1 could be an attractive therapeutic strategy to improve outcomes in HPV-negative HNSCC, the high co-expression of these genes obscures their individual impact on radio and chemo-resistance. This evidence concerns the gene CCND1 and head and neck squamous cell carcinoma.